Pseudomonas Aeruginosa Infection Treatment Market Insights, Revenue Analysis, and Future Outlook | Valuates Reports
Unlock 20% Off Global Market Reports Using Code ONLINE20 – Stay Informed on Trade Policies, Market Growth, and Key Disruptors
What Is the Forecast Market Size and Growth Rate of the Pseudomonas Aeruginosa Infection Treatment Market by Region?
The pseudomonas aeruginosa infection treatment market size has grown strongly in recent years. It will grow from $2.45 billion in 2024 to $2.65 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to rising incidence of nosocomial infections, growing antibiotic resistance concerns, increased healthcare expenditure, expansion of hospital and healthcare facilities, focus on early diagnosis and intervention.
The pseudomonas aeruginosa infection treatment market size is expected to see strong growth in the next few years. It will grow to $3.61 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increased research on antimicrobial peptides, focus on therapeutic efficacy and safety, rise in cases of multidrug-resistant paeruginosa, patient-centric approaches in treatment development, regulatory incentives. Major trends in the forecast period include combination therapies, advancements in drug delivery, point-of-care diagnostics, integration of genomic data in treatment strategies, global collaboration in antibiotic research.
Claim your free report sample now:
What Are the Top Drivers and Growth Contributors in the Pseudomonas Aeruginosa Infection Treatment Market?
The increasing incidence of co-morbidities such as pneumonia, cystic fibrosis, urinary tract infection, and bloodstream infection is expected to propel the growth of the pseudomonas aeruginosa infection treatment market going forward. Comorbidity refers to any concurrent medical condition. Comorbidities are frequently chronic conditions that can affect either physical or mental health. For instance, in August 2022, according to an article published by the National Library of Medicine, a US-based biomedical library and the center of computational biology and biomedical informatics, the incidence rate of community-acquired pneumonia in the US is 24.8 instances per 10,000 adult population annually, with rates rising with advancing age. Pneumonia is the eighth most common cause of death and the leading infectious cause of death. Patients hospitalized in the intensive care unit have a death rate as high as 23%. Therefore, the increasing incidence of co-morbidities such as pneumonia, cystic fibrosis, urinary tract infection, and bloodstream infection is driving the growth of the pseudomonas aeruginosa infection treatment market.
What Are the Major Product/Service Segments in the Pseudomonas Aeruginosa Infection Treatment Market?
The pseudomonas aeruginosa infection treatment market covered in this report is segmented –
1) By Medication: Monotherapy, Combination Therapy
2) By Drug Class: Aminoglycoside, Cephalosporin, Carbapenem, Monobactum, Other Drug Classes
3) By Route Of Administration: Nasal, Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Monotherapy: Antibiotics, Antipseudomonal Agents
2) By Combination Therapy: Beta-lactam And Aminoglycoside Combinations, Beta-lactam And Fluoroquinolone Combinations, Other Combinations
What Are the Major Trends Impacting the Pseudomonas Aeruginosa Infection Treatment Market?
Major companies operating in the pseudomonas aeruginosa infection treatment market are investing in personalized or targeted treatments such as precision antibiotic therapies to sustain their position in the market. Precision antibiotic therapies are targeted treatments that use engineered proteins like bacteriocins to specifically attack antibiotic-resistant bacteria. For instance, in November 2023, Glox Therapeutics Ltd., a Scotland-based pharmaceutical company, raised $5.25 million (£4.3 million) in seed funding to develop precision antibiotic therapies targeting antibiotic-resistant bacteria using bacteriocins—naturally occurring antimicrobial proteins. The funding will support the establishment of labs in Oxford and Glasgow and expand the research team. Glox's research focuses on targeting resistant Gram-negative pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae, which contribute to the global antimicrobial resistance crisis, claiming 1.27 million lives annually.
Who Are the Industry Leaders in the Pseudomonas Aeruginosa Infection Treatment Market?
Major companies operating in the pseudomonas aeruginosa infection treatment market include AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co Inc., Janssen Pharmaceutica NV, Pfizer Inc., Lupin Limited, AstraZeneca plc, Bristol Myers Squibb Company, Gilead Sciences Inc., Novartis Pharmaceuticals Corporation, F. Hoffmann-La Roche AG, Bayer AG, Johnson & Johnson, Baxter International Inc., Neopharma LLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Cipla Inc., Hikma Pharmaceuticals plc, Zydus Cadila Healthcare Limited, Wockhardt Ltd., Mayne Pharma Group Limited, Glenmark Pharmaceuticals Ltd., Perrigo Company plc, Amneal Pharmaceuticals LLC, Apotex Inc., Bausch Health Companies Inc., Biocon Ltd., Cadila Healthcare Ltd.
Get the full pseudomonas aeruginosa infection treatment market report here:
Which Region Is Expected to Lead the Pseudomonas Aeruginosa Infection Treatment Market by 2029?
Europe was the largest region in the pseudomonas aeruginosa infection treatment market in 2024. North America is expected to be the fastest-growing region in the pseudomonas aeruginosa infection treatment market report during the forecast period. The regions covered in the pseudomonas aeruginosa infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment